Weekly Promotions

• C-Reactive Protein (CRP) [ 4420 ]
• CBC (includes Differential and Platelets) [ 6399 ]
• Comprehensive Metabolic Panel (CMP) [ 10231 ]
• Glucose (included in CMP)
• Hemoglobin A1c (HgbA1C) [ 496 ]
• Insulin [ 561 ]
• Lipid Panel [ 7600 ]
• Microalbumin, Random Urine with Creatinine [ 6517 ]

• Adiponectin [ 15060 ]
• C-Peptide [ 372 ]
• Fructosamine [ 8340 ]
• Glutamic Acid Decarboxylase-65 Antibody [ 34878 ]
• GlycoMark® [ 19599 ]
• Proinsulin [ 760 ]
• Urinalysis (UA), Complete [ 5463 ]
   

• C-Reactive Protein (CRP) [ 4420 ]
• CBC (includes Differential and Platelets) [ 6399 ]
• Comprehensive Metabolic Panel (CMP) [ 10231 ]
• Glucose (included in CMP)
• Glucose Tolerance Test, 2 Specimens (75g) [ 35181 ]
• Hemoglobin A1c (HgbA1C) [ 496 ]
• Insulin [ 561 ]
• Insulin Response to Glucose, 2 Specimens [ 6697 ]
• Lipid Panel [ 7600 ]
• Microalbumin, Random Urine with Creatinine [ 6517 ]

• Adiponectin [ 15060 ]
• Apolipoprotein A1 + B [ 7018 ]
• C-Peptide [ 372 ]
• Fructosamine [ 8340 ]
• Glutamic Acid Decarboxylase-65 Antibody [ 34878 ]
• GlycoMark® [ 19599 ]
• IA-2 Antibody [ 36177 ]
• Lipoprotein Fractionation, Ion Mobility, Cardio IQ™ [ 91604 ]
• Proinsulin [ 760 ]
• Urinalysis (UA), Complete [ 5463 ]
   

A Hemoglobin (Hb) A1c Blood Test evaluates the average amount of glucose in the blood. The A1c test will help determine whether you are at a higher risk of developing diabetes; to help diagnose diabetes and prediabetes; to monitor diabetes and to aid in treatment decisions.

To assist with control of blood glucose levels, the American Diabetes Association (ADA) has recommended glycated hemoglobin testing (HbA1c) twice a year for patients with stable glycemia, and quarterly for patients with poor glucose control. Interpretative ranges are based on ADA guidelines.

Measurement of serum 25-OH vitamin D concentrations provide a good index of circulating vitamin D activity in patients not suffering from renal disease. Lower than normal 25-OH vitamin D levels can result from a dietary deficiency, poor absorption of the vitamin or impaired metabolism of the sterol in the liver. A 25-OH vitamin D deficiency can lead to bone diseases such as rickets and osteomalacia. Above normal levels can lead hypercalcemia.

The 10 Key Lab Tests to Review with Your Doctor™ panel contains 17 tests with 78 biomarkers. 

1. Apolipoprotein B, Cardio IQ
2. C-Reactive Protein (CRP) 
3. CBC (includes Differential and Platelets) 
4. Hemoglobin A1c, Cardio IQ™
5. hs-CRP, Cardio IQ™
6. Lipid Panel, Cardio IQ™
7. QuestAssureD™ 25-Hydroxyvitamin D (D2, D3)
8. TSH, Free T3 and Free T4 Blood Test Panel
9. Ferritin, Iron & Total Iron Binding Capacity -TIBC
10. BCA Chemistry Panel
    • Gamma Glutamyl Transferase (GGT) 
    • Comprehensive Metabolic Panel (CMP)
    • Lactate Dehydrogenase (LD) 
    • Phosphate (as Phosphorus) 
    • Uric Acid
    • Glucose
    • Magnesium

The Digestive Health - Advanced contains the following tests

• C-Reactive Protein (CRP) 
• CBC (includes Differential and Platelets) 
• Comprehensive Metabolic Panel (CMP)
• Fecal Globin by Immunochemistry (InSure®) 
• Ferritin
• Folate, Serum
• Iron and Total Iron Binding Capacity (TIBC)
• QuestAssureD™ 25-Hydroxyvitamin D (D2, D3), LC/MS/MS 
• Transferrin
• Vitamin B12 (Cobalamin) 
• Celiac Disease Comprehensive Panel (w/ Reflexes)

Specimens from children less than 4 years of age (i.e., less than 48 months) are not appropriate for this test. The test for children 4 years of age and younger is the Celiac Disease Comprehensive Panel, Infant (test code 15981).

Includes

Tissue Transglutaminase, IgA with Reflexes; Total IgA with Reflex

IMPORTANT - Note this is Reflex Test which if additional tests are run you will be charged for the specific tests that the lab peforms. Additional test will be run if the following criteria are met.

If the Tissue Transglutaminase IgA is positive, 

1. Endomysial Antibody Screen (IgA) will be performed at an additional charge (CPT code(s): 86255).

If the Endomysial Antibody Screen (IgA) is positive, 

2. Endomysial Antibody Titer will be performed at an additional charge (CPT code(s): 86256).

If the Total IgA is less than the lower limit of the reference range, based on age, 

3. Tissue Transglutaminase IgG will be performed at an additional charge (CPT code(s): 83516).

Clinical Significance

Celiac disease is caused by an immune response to gluten in genetically sensitive individuals. The diagnosis is largely based on a biopsy of the small intestine, but serologic tests also help support a diagnosis and may assist identification of patients who may require biopsy.

Tissue transglutaminase antibodies (tTG, IgA) is a marker with 95% sensitivity and specificity. Total IgA is measured because 2-3% of celiac disease patients are IgA deficient. Because tTG, IgA, and anti-Gliadin IgA tend to decrease in patients on a gluten-free diet, these markers are also used to assess dietary compliance.

The endomysial antibody (EMA, IgA) assay has high specificity for celiac disease and is used to confirm positive anti-tTG results.

Digestive Health - Basic contains the following tests

• CBC (includes Differential and Platelets) 
• Comprehensive Metabolic Panel (CMP)
• Fecal Globin by Immunochemistry (InSure®) 
• Celiac Disease Comprehensive Panel (w/ Reflexes)

Specimens from children less than 4 years of age (i.e., less than 48 months) are not appropriate for this test. The test for children 4 years of age and younger is the Celiac Disease Comprehensive Panel, Infant (test code 15981).

Includes

Tissue Transglutaminase, IgA with Reflexes; Total IgA with Reflex

IMPORTANT - Note this is Reflex Test which if additional tests are run you will be charged for the specific tests that the lab peforms. Additional test will be run if the following criteria are met.

If the Tissue Transglutaminase IgA is positive, 

1. Endomysial Antibody Screen (IgA) will be performed at an additional charge (CPT code(s): 86255).

If the Endomysial Antibody Screen (IgA) is positive, 

2. Endomysial Antibody Titer will be performed at an additional charge (CPT code(s): 86256).

If the Total IgA is less than the lower limit of the reference range, based on age, 

3. Tissue Transglutaminase IgG will be performed at an additional charge (CPT code(s): 83516).

Clinical Significance

Celiac disease is caused by an immune response to gluten in genetically sensitive individuals. The diagnosis is largely based on a biopsy of the small intestine, but serologic tests also help support a diagnosis and may assist identification of patients who may require biopsy.

Tissue transglutaminase antibodies (tTG, IgA) is a marker with 95% sensitivity and specificity. Total IgA is measured because 2-3% of celiac disease patients are IgA deficient. Because tTG, IgA, and anti-Gliadin IgA tend to decrease in patients on a gluten-free diet, these markers are also used to assess dietary compliance.

The endomysial antibody (EMA, IgA) assay has high specificity for celiac disease and is used to confirm positive anti-tTG results.

Digestive Health - Basic Plus contains the followwing tests: 

• C-Reactive Protein (CRP) 
• CBC (includes Differential and Platelets) 
• Comprehensive Metabolic Panel (CMP)
• Fecal Globin by Immunochemistry (InSure®) 
• Ferritin
• Iron and Total Iron Binding Capacity (TIBC)
• Celiac Disease Comprehensive Panel (w/ Reflexes)

 Specimens from children less than 4 years of age (i.e., less than 48 months) are not appropriate for this test. The test for children 4 years of age and younger is the Celiac Disease Comprehensive Panel, Infant (test code 15981).

Includes

Tissue Transglutaminase, IgA with Reflexes; Total IgA with Reflex

IMPORTANT - Note this is Reflex Test which if additional tests are run you will be charged for the specific tests that the lab peforms. Additional test will be run if the following criteria are met.

If the Tissue Transglutaminase IgA is positive, 

1. Endomysial Antibody Screen (IgA) will be performed at an additional charge (CPT code(s): 86255).

If the Endomysial Antibody Screen (IgA) is positive, 

2. Endomysial Antibody Titer will be performed at an additional charge (CPT code(s): 86256).

If the Total IgA is less than the lower limit of the reference range, based on age, 

3. Tissue Transglutaminase IgG will be performed at an additional charge (CPT code(s): 83516).

Clinical Significance

Celiac disease is caused by an immune response to gluten in genetically sensitive individuals. The diagnosis is largely based on a biopsy of the small intestine, but serologic tests also help support a diagnosis and may assist identification of patients who may require biopsy.

Tissue transglutaminase antibodies (tTG, IgA) is a marker with 95% sensitivity and specificity. Total IgA is measured because 2-3% of celiac disease patients are IgA deficient. Because tTG, IgA, and anti-Gliadin IgA tend to decrease in patients on a gluten-free diet, these markers are also used to assess dietary compliance.

The endomysial antibody (EMA, IgA) assay has high specificity for celiac disease and is used to confirm positive anti-tTG results.

Digestive Health - Comprehensive contains the following tests: 

• C-Reactive Protein (CRP) 
• CBC (includes Differential and Platelets) 
• Comprehensive Metabolic Panel (CMP)
• Fecal Globin by Immunochemistry (InSure®) 
• Ferritin
• Folate, Serum
• Gliadin (Deamidated Peptide) Antibody (IgA) 
• Gliadin (Deamidated Peptide) Antibody (IgG) 
• Iron and Total Iron Binding Capacity (TIBC)
• Lipid Panel with Ratios
• Magnesium
• Prealbumin 
• QuestAssureD™ 25-Hydroxyvitamin D (D2, D3), LC/MS/MS 
• Transferrin
• TSH
• Vitamin A (Retinol)
• Vitamin B12 (Cobalamin) 
• Vitamin K
• Celiac Disease Comprehensive Panel (w/ Reflexes)

Specimens from children less than 4 years of age (i.e., less than 48 months) are not appropriate for this test. The test for children 4 years of age and younger is the Celiac Disease Comprehensive Panel, Infant (test code 15981).

Includes

Tissue Transglutaminase, IgA with Reflexes; Total IgA with Reflex

IMPORTANT - Note this is Reflex Test which if additional tests are run you will be charged for the specific tests that the lab peforms. Additional test will be run if the following criteria are met.

If the Tissue Transglutaminase IgA is positive, 

1. Endomysial Antibody Screen (IgA) will be performed at an additional charge (CPT code(s): 86255).

If the Endomysial Antibody Screen (IgA) is positive, 

2. Endomysial Antibody Titer will be performed at an additional charge (CPT code(s): 86256).

If the Total IgA is less than the lower limit of the reference range, based on age, 

3. Tissue Transglutaminase IgG will be performed at an additional charge (CPT code(s): 83516).

Clinical Significance

Celiac disease is caused by an immune response to gluten in genetically sensitive individuals. The diagnosis is largely based on a biopsy of the small intestine, but serologic tests also help support a diagnosis and may assist identification of patients who may require biopsy.

Tissue transglutaminase antibodies (tTG, IgA) is a marker with 95% sensitivity and specificity. Total IgA is measured because 2-3% of celiac disease patients are IgA deficient. Because tTG, IgA, and anti-Gliadin IgA tend to decrease in patients on a gluten-free diet, these markers are also used to assess dietary compliance.

The endomysial antibody (EMA, IgA) assay has high specificity for celiac disease and is used to confirm positive anti-tTG results.

IMPORTANT - Note the Estradiol test included in this panel is not for children that have yet to start their menstrual cycle.  If this test is ordered for a child that has yet to begin their menstrual cycle Quest Diagnostics labs will substitute Estradiol, Free, LC/MS/MS at an additional fee of $290.00

IMPORTANT - Note the Estradiol test included in this panel is not for children that have yet to start their menstrual cycle.  If this test is ordered for a child that has yet to begin their menstrual cycle Quest Diagnostics labs will substitute Estradiol, Free, LC/MS/MS at an additional fee of $290.00

IMPORTANT - Note the Estradiol test included in this panel is not for children that have yet to start their menstrual cycle.  If this test is ordered for a child that has yet to begin their menstrual cycle Quest Diagnostics labs will substitute Estradiol, Free, LC/MS/MS at an additional fee of $290.00

IMPORTANT - Note the Estradiol test included in this panel is not for children that have yet to start their menstrual cycle.  If this test is ordered for a child that has yet to begin their menstrual cycle Quest Diagnostics labs will substitute Estradiol, Free, LC/MS/MS at an additional fee of $290.00

IMPORTANT - Note the Estradiol test included in this panel is not for children that have yet to start their menstrual cycle.  If this test is ordered for a child that has yet to begin their menstrual cycle Quest Diagnostics labs will substitute Estradiol, Free, LC/MS/MS at an additional fee of $290.00

The Digestive Health - Advanced contains the following tests

• C-Reactive Protein (CRP) 
• CBC (includes Differential and Platelets) 
• Comprehensive Metabolic Panel (CMP)
• Fecal Globin by Immunochemistry (InSure®) 
• Ferritin
• Folate, Serum
• Iron and Total Iron Binding Capacity (TIBC)
• QuestAssureD™ 25-Hydroxyvitamin D (D2, D3), LC/MS/MS 
• Transferrin
• Vitamin B12 (Cobalamin) 
• Celiac Disease Comprehensive Panel (w/ Reflexes)

Specimens from children less than 4 years of age (i.e., less than 48 months) are not appropriate for this test. The test for children 4 years of age and younger is the Celiac Disease Comprehensive Panel, Infant (test code 15981).

Includes

Tissue Transglutaminase, IgA with Reflexes; Total IgA with Reflex

IMPORTANT - Note this is Reflex Test which if additional tests are run you will be charged for the specific tests that the lab peforms. Additional test will be run if the following criteria are met.

If the Tissue Transglutaminase IgA is positive, 

1. Endomysial Antibody Screen (IgA) will be performed at an additional charge (CPT code(s): 86255).

If the Endomysial Antibody Screen (IgA) is positive, 

2. Endomysial Antibody Titer will be performed at an additional charge (CPT code(s): 86256).

If the Total IgA is less than the lower limit of the reference range, based on age, 

3. Tissue Transglutaminase IgG will be performed at an additional charge (CPT code(s): 83516).

Clinical Significance

Celiac disease is caused by an immune response to gluten in genetically sensitive individuals. The diagnosis is largely based on a biopsy of the small intestine, but serologic tests also help support a diagnosis and may assist identification of patients who may require biopsy.

Tissue transglutaminase antibodies (tTG, IgA) is a marker with 95% sensitivity and specificity. Total IgA is measured because 2-3% of celiac disease patients are IgA deficient. Because tTG, IgA, and anti-Gliadin IgA tend to decrease in patients on a gluten-free diet, these markers are also used to assess dietary compliance.

The endomysial antibody (EMA, IgA) assay has high specificity for celiac disease and is used to confirm positive anti-tTG results.

Digestive Health - Comprehensive contains the following tests: 

• C-Reactive Protein (CRP) 
• CBC (includes Differential and Platelets) 
• Comprehensive Metabolic Panel (CMP)
• Fecal Globin by Immunochemistry (InSure®) 
• Ferritin
• Folate, Serum
• Gliadin (Deamidated Peptide) Antibody (IgA) 
• Gliadin (Deamidated Peptide) Antibody (IgG) 
• Iron and Total Iron Binding Capacity (TIBC)
• Lipid Panel with Ratios
• Magnesium
• Prealbumin 
• QuestAssureD™ 25-Hydroxyvitamin D (D2, D3), LC/MS/MS 
• Transferrin
• TSH
• Vitamin A (Retinol)
• Vitamin B12 (Cobalamin) 
• Vitamin K
• Celiac Disease Comprehensive Panel (w/ Reflexes)

Specimens from children less than 4 years of age (i.e., less than 48 months) are not appropriate for this test. The test for children 4 years of age and younger is the Celiac Disease Comprehensive Panel, Infant (test code 15981).

Includes

Tissue Transglutaminase, IgA with Reflexes; Total IgA with Reflex

IMPORTANT - Note this is Reflex Test which if additional tests are run you will be charged for the specific tests that the lab peforms. Additional test will be run if the following criteria are met.

If the Tissue Transglutaminase IgA is positive, 

1. Endomysial Antibody Screen (IgA) will be performed at an additional charge (CPT code(s): 86255).

If the Endomysial Antibody Screen (IgA) is positive, 

2. Endomysial Antibody Titer will be performed at an additional charge (CPT code(s): 86256).

If the Total IgA is less than the lower limit of the reference range, based on age, 

3. Tissue Transglutaminase IgG will be performed at an additional charge (CPT code(s): 83516).

Clinical Significance

Celiac disease is caused by an immune response to gluten in genetically sensitive individuals. The diagnosis is largely based on a biopsy of the small intestine, but serologic tests also help support a diagnosis and may assist identification of patients who may require biopsy.

Tissue transglutaminase antibodies (tTG, IgA) is a marker with 95% sensitivity and specificity. Total IgA is measured because 2-3% of celiac disease patients are IgA deficient. Because tTG, IgA, and anti-Gliadin IgA tend to decrease in patients on a gluten-free diet, these markers are also used to assess dietary compliance.

The endomysial antibody (EMA, IgA) assay has high specificity for celiac disease and is used to confirm positive anti-tTG results.

IMPORTANT - Note the Estradiol test included in this panel is not for children that have yet to start their menstrual cycle.  If this test is ordered for a child that has yet to begin their menstrual cycle Quest Diagnostics labs will substitute Estradiol, Free, LC/MS/MS at an additional fee of $290.00

IMPORTANT - Note the Estradiol test included in this panel is not for children that have yet to start their menstrual cycle.  If this test is ordered for a child that has yet to begin their menstrual cycle Quest Diagnostics labs will substitute Estradiol, Free, LC/MS/MS at an additional fee of $290.00

ABO Group and Rh Type

Blood typing is used to determine an individual's blood group, to establish whether a person is blood group A, B, AB, or O and whether he or she is Rh positive or Rh negative.

The Different Blood Types

There are four major blood groups and eight different blood types. Doctors call this the ABO Blood Group System.

The groups are based on whether or not you have two specific antigens -- A and B:

• Group A has the A antigen and B antibody.
• Group B has the B antigen and the A antibody.
• Group AB has A and B antigens but neither A nor B antibodies.
• Group O doesn’t have A or B antigens but has both A and B antibodies.

There’s also a third kind of antigen called the Rh factor. You either have this antigen (meaning your blood type is “Rh+” or “positive”), or you don’t (meaning your blood type is “Rh-” or “negative”). So, from the four blood groups, there are eight blood types:

• A positive or A negative
• B positive or B negative
• AB positive or AB negative
• O positive or O negative

• Ceruloplasmin
• Comprehensive Metabolic Panel (CMP)
• Copper
• Glucose (Included as part of the CMP)
• Hemoglobin A1c (HgbA1C)
• Homocysteine
• hs-CRP
• Insulin
• Iron and Total Iron Binding Capacity (TIBC)
• Lead, Blood
• Mercury, Blood
• QuestAssureD™ 25-Hydroxyvitamin D (D2, D3), LC/MS/MS
• Vitamin B12 (Cobalamin) and Folate Panel, Serum
• Zinc

The Breast Health Foundation Panel 

INFLAMATION

• Creatine Kinase (CK), Total
• hs-CRP
• Lactate Dehydrogenase (LD)
• Sed Rate by Modified Westergren (ESR)

METABOLISM

• Glucose
• Hemoglobin A1c (HgbA1C)

NUTRIENTS

• Ferritin
• Iron and Total Iron Binding Capacity (TIBC)
• Vitamin B12 (Cobalamin)
• Vitamin D, 25-Hydroxy, Total, Immunoassay

CORE TESTS

• ABO Group and Rh Type
• CBC (includes Differential and Platelets)
• Comprehensive Metabolic Panel (CMP)

The Breast Health Foundation Panel 

INFLAMATION

• Creatine Kinase (CK), Total
• hs-CRP
• Lactate Dehydrogenase (LD)
• Sed Rate by Modified Westergren (ESR)

METABOLISM

• Glucose
• Hemoglobin A1c (HgbA1C)

NUTRIENTS

• Ferritin
• Iron and Total Iron Binding Capacity (TIBC)
• Vitamin B12 (Cobalamin)
• Vitamin D, 25-Hydroxy, Total, Immunoassay

CORE TESTS

• ABO Group and Rh Type
• CBC (includes Differential and Platelets)
• Comprehensive Metabolic Panel (CMP)

CANCER

• CA 15-3

• Alpha-Fetoprotein (AFP) and AFP-L3 [ 19529 ]
• CA 19-9 [ 4698 ]
• PSA, Free and Total [ 31348 ]

• Alpha-Fetoprotein (AFP) and AFP-L3 [ 19529 ]
• Amylase [ 243 ]
• CA 19-9 [ 4698 ]
• CBC (includes Differential and Platelets) [ 6399 ]
• CEA [ 978 ]
• Lactate Dehydrogenase (LD) [ 593 ]
• PSA, Free and Total [ 31348 ]
• Thyroglobulin Antibodies (TgAb) [ 267 ]
   

• Alpha-Fetoprotein (AFP) and AFP-L3 [ 19529 ]
• Amylase [ 243 ]
• CA 19-9 [ 4698 ]
• CBC (includes Differential and Platelets) [ 6399 ]
• CEA [ 978 ]
• Fecal Globin by Immunochemistry (InSure®) [ 11290 ]
• Gastrin [ 478 ]
• hCG, Total, Quantitative [ 8396 ]
• Lactate Dehydrogenase (LD) [ 593 ]
• PSA, Free and Total [ 31348 ]
• Thyroglobulin Antibodies (TgAb) [ 267 ]
   

• Alpha-Fetoprotein (AFP) and AFP-L3 [ 19529 ]
• Amylase [ 243 ]
• CA 19-9 [ 4698 ]
• Calcitonin [ 30742 ]
• CBC (includes Differential and Platelets) [ 6399 ]
• CEA [ 978 ]
• DCP (Des-Gamma-Carboxy-Prothrombin) [ 19982 ]
• Fecal Globin by Immunochemistry (InSure®) [ 11290 ]
• Gastrin [ 478 ]
• hCG, Total, Quantitative [ 8396 ]
• Lactate Dehydrogenase (LD) [ 593 ]
• PSA, Free and Total [ 31348 ]
• Thyroglobulin Antibodies (TgAb) [ 267 ]
   

A Complete Blood Count (CBC) Panel is used as a screening test for various disease states including anemia, leukemia and inflammatory processes.

A CBC blood test includes the following biomarkers: WBC, RBC, Hemoglobin, Hematocrit, MCV, MCH, MCHC, RDW, Platelet count, Neutrophils, Lymphs, Monocytes, Eos, Basos, Neutrophils (Absolute), Lymphs (Absolute), Monocytes(Absolute), Eos (Absolute), Basos (Absolute), Immature Granulocytes, Immature Grans (Abs)

Lactate Dehydrogenase (LD) (LDH)

Elevations in serum lactate dehydrogenase occur from myocardial infarction, liver disease, pernicious and megaloblastic anemia, pulmonary emboli, malignancies, and muscular dystrophy

• Alpha-Fetoprotein (AFP) and AFP-L3 [ 19529 ]
• CA 125 [ 29256 ]
• CA 15-3 [ 5819 ]
• CA 19-9 [ 4698 ]
• CA 27.29 [ 29493 ]

• Alpha-Fetoprotein (AFP) and AFP-L3 [ 19529 ]
• Amylase [ 243 ]
• CA 125 [ 29256 ]
• CA 15-3 [ 5819 ]
• CA 19-9 [ 4698 ]
• CA 27.29 [ 29493 ]
• CBC (includes Differential and Platelets) [ 6399 ]
• CEA [ 978 ]
• Lactate Dehydrogenase (LD) [ 593 ]
• Thyroglobulin Antibodies (TgAb) [ 267 ]
   

• Alpha-Fetoprotein (AFP) and AFP-L3 [ 19529 ]
• Amylase [ 243 ]
• CA 125 [ 29256 ]
• CA 15-3 [ 5819 ]
• CA 19-9 [ 4698 ]
• CA 27.29 [ 29493 ]
• CBC (includes Differential and Platelets) [ 6399 ]
• CEA [ 978 ]
• Fecal Globin by Immunochemistry (InSure®) [ 11290 ]
• Gastrin [ 478 ]
• hCG, Total, Quantitative [ 8396 ]
• Lactate Dehydrogenase (LD) [ 593 ]
• Thyroglobulin Antibodies (TgAb) [ 267 ]
   

• Alpha-Fetoprotein (AFP) and AFP-L3 [ 19529 ]
• Amylase [ 243 ]
• CA 125 [ 29256 ]
• CA 15-3 [ 5819 ]
• CA 19-9 [ 4698 ]
• CA 27.29 [ 29493 ]
• Calcitonin [ 30742 ]
• CBC (includes Differential and Platelets) [ 6399 ]
• CEA [ 978 ]
• CHROMOGRANIN A [ 16379 ]
• DCP (Des-Gamma-Carboxy-Prothrombin) [ 19982 ]
• Fecal Globin by Immunochemistry (InSure®) [ 11290 ]
• Gastrin [ 478 ]
• hCG, Total, Quantitative [ 8396 ]
• Lactate Dehydrogenase (LD) [ 593 ]
• Protein, Total And Protein Electrophoresis (Refl) [ 23036 ]
• Thyroglobulin Antibodies (TgAb) [ 267 ]
   

A Complete Blood Count (CBC) Panel is used as a screening test for various disease states including anemia, leukemia and inflammatory processes.

A CBC blood test includes the following biomarkers: WBC, RBC, Hemoglobin, Hematocrit, MCV, MCH, MCHC, RDW, Platelet count, Neutrophils, Lymphs, Monocytes, Eos, Basos, Neutrophils (Absolute), Lymphs (Absolute), Monocytes(Absolute), Eos (Absolute), Basos (Absolute), Immature Granulocytes, Immature Grans (Abs)

Lactate Dehydrogenase (LD) (LDH)

Elevations in serum lactate dehydrogenase occur from myocardial infarction, liver disease, pernicious and megaloblastic anemia, pulmonary emboli, malignancies, and muscular dystrophy

Measuring Lipid Subclasses using Ion Mobility

The way most doctors test for heart disease is with a lipid panel. It helps detect what HDL (good) and LDL (bad) cholesterol are, so hopefully you can reduce your risk of a possible cardiac event such as a heart attack. Nearly half of all heart attack patients were found to have no prior risk which would indicate they were heading toward an attack.

Quest Diagnostics offers advanced cardiovascular tests that help provide a more accurate and individualized picture of risk. The tests look beyond just HDL and LDL cholesterol to identify undiagnosed (or additional) risk.

These advanced cardiovascular tests, along with your lipid panel, will provide more information that you and your doctor can use to understand your complete cardiovascular health.

Lipid Subclasses as measured by Ion Mobility Technology

Knowing what particles make up your LDL and HDL cholesterol may be important. Ion Mobility Technology provides subclass separation that will allow your healthcare provider to identify your cardiovascular risk over time. Following the change in your lipid profile as you respond to diet, exercise and possible medication to reduce your cardiovascular risk is important. Ion Mobility provides the opportunity to determine if treatment is working and if not, optimize the aggressiveness of therapy to hopefully make a difference that can be seen in the Ion Mobility measurement and graphical representation of your LDL and HDL particles. 

Cardio IQ™ Lipoprotein Fractionation, Ion Mobility 
Cardio IQ™ Lipid Panel
Cardio IQ™ Direct LDL 
Cardio IQ™ Apolipoprotein Evaluation 
Cardio IQ™ Lipoprotein (A)

Apo B

• Apo B is a direct measurement of the number of lipoprotein particles, including LDL (“bad cholesterol”), IDL, and VLDL
• A high Apo B number indicates increased risk for heart disease
• Certain medications, improved eating habits, increased physical activity, and loss of body fat are some ways to
  improve Apo B

Lipoprotein (A) - Lp(a)

• High levels of Lp(a) are associated with increased risk of cardiovascular disease and stroke
• Lp(a) levels may be influenced by genetics. Diet and exercise have limited to no effect on lowering Lp(a); however, certain
  medications can lower levels

Cardio IQ® Apolipoprotein Evaluation - (APOLIPOPROTEIN A1, APOLIPOPROTEIN B and APOLIPOPROTEIN B/A1 RATIO)

• Apolipoprotein A1 is the primary protein associated with HDL cholesterol. Like HDL cholesterol, increased concentrations are associated with reduced risk of cardiovascular disease. Apolipoprotein B-100 is the primary protein associated with LDL cholesterol and other lipid particles. Like LDL cholesterol, increased concentrations are associated with increased risk of cardiovascular disease. The ratio of these two apolipoproteins correlates with risk of cardiovascular disease.

Cardio IQ Advanced Lipid Panel Plus and Inflammation Panel

Measuring Lipid Subclasses using Ion Mobility

The way most doctors test for heart disease is with a lipid panel. It helps detect what HDL (good) and LDL (bad) cholesterol are, so hopefully you can reduce your risk of a possible cardiac event such as a heart attack. Nearly half of all heart attack patients were found to have no prior risk which would indicate they were heading toward an attack.

Quest Diagnostics offers advanced cardiovascular tests that help provide a more accurate and individualized picture of risk. The tests look beyond just HDL and LDL cholesterol to identify undiagnosed (or additional) risk.

These advanced cardiovascular tests, along with your lipid panel, will provide more information that you and your doctor can use to understand your complete cardiovascular health.

Lipid Subclasses as measured by Ion Mobility Technology

Knowing what particles make up your LDL and HDL cholesterol may be important. Ion Mobility Technology provides subclass separation that will allow your healthcare provider to identify your cardiovascular risk over time. Following the change in your lipid profile as you respond to diet, exercise and possible medication to reduce your cardiovascular risk is important. Ion Mobility provides the opportunity to determine if treatment is working and if not, optimize the aggressiveness of therapy to hopefully make a difference that can be seen in the Ion Mobility measurement and graphical representation of your LDL and HDL particles. 

Cardio IQ™ Lipoprotein Fractionation, Ion Mobility 

Cardio IQ™ Lipid Panel

Cardio IQ™ Direct LDL 

Cardio IQ™ Apolipoprotein Evaluation 

Cardio IQ™ Lipoprotein (A)

Apo B

• Apo B is a direct measurement of the number of lipoprotein particles, including LDL (“bad cholesterol”), IDL, and VLDL
• A high Apo B number indicates increased risk for heart disease
• Certain medications, improved eating habits, increased physical activity, and loss of body fat are some ways to
  improve Apo B

Lipoprotein (A) - Lp(a)

• High levels of Lp(a) are associated with increased risk of cardiovascular disease and stroke
• Lp(a) levels may be influenced by genetics. Diet and exercise have limited to no effect on lowering Lp(a); however, certain
  medications can lower levels

Cardio IQ® Apolipoprotein Evaluation - (APOLIPOPROTEIN A1, APOLIPOPROTEIN B and APOLIPOPROTEIN B/A1 RATIO)

• Apolipoprotein A1 is the primary protein associated with HDL cholesterol. Like HDL cholesterol, increased concentrations are associated with reduced risk of cardiovascular disease. Apolipoprotein B-100 is the primary protein associated with LDL cholesterol and other lipid particles. Like LDL cholesterol, increased concentrations are associated with increased risk of cardiovascular disease. The ratio of these two apolipoproteins correlates with risk of cardiovascular disease.

Inflammation Panel

hs-CRP

• High levels of C-Reactive Protein (CRP) indicate inflammation due to infection or tissue injury
• Modestly elevated CRP levels may be associated with increased heart disease risk. If both CRP and Lp-PLA2 levels are
  high, your risk for a heart attack or stroke increases significantly
• Certain medications and food may have anti-inflammatory benefits

Lp-PLA2

• High levels of Lp-PLA2 can predict risk of a heart attack or stroke
• When both Lp-PLA2 levels and systolic blood pressure are high, stroke risk increases significantly
• Certain medications can reduce levels of Lp-PLA2 

• CARDIO IQ(R) LP PLA2 ACTIVITY
• hs-CRP, Cardio IQ™
• Lipid Panel, Cardio IQ™
• Lipoprotein (a), Cardio IQ™
• Lipoprotein Fractionation, Ion Mobility, Cardio IQ™

Cardio IQ® ASCVD Risk Panel with Score 

This panel provides the 10-year and lifetime risk of atherosclerotic cardiovascular disease (ASCVD) using lipid results with anthropomorphic data and family history. 
The ASCVD risk assessment is recommended in the 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults.

IMPORTANT: For risk calculations to be performed, the following patient-specific information must be provided and recorded at the time of specimen collection:

• Age: Years 
• Gender: M (for male) or F (for female) 
• Height Feet: Feet 
• Height Inches: Inches 
• Weight: lbs 
• Race-African American: Y (for yes) or N (for no) 
• Systolic Blood Pressure: mmHg
• Diastolic Blood Pressure: mmHg
• Treatment for High B.P.: Y (for yes) or N (for no) 
• Diabetes Status: Y (for yes) or N (for no)
• Parental History of Diab: Y (for yes) or N (for no) 
• Smoking Status: Y (for Yes) or N (for no)

Cardio IQ® Diabetes and ASCVD Risk Panel with Scores - Includes:  Cardio IQ® Glucose; Cardio IQ® Hemoglobin A1c; Cardio IQ® Cholesterol, Total; Cardio IQ® HDL Cholesterol; Cardio IQ® Triglycerides; Cardio IQ® Non-HDL and Calculated Components; Cardio IQ® Risks and Personal Factors

If Triglyceride is >400 mg/dL, Cardio IQ® Direct LDL will be performed at an additional charge (CPT code(s): 83721).

Clinical Significance

The increasing prevalence of obesity has led to an epidemic of diabetes mellitus and related complications, including ASCVD. Prediction of the risk of ASCVD and of developing diabetes in the Cardio IQ® lab report will simplify and improve the communication of those risks to patients.

This panel provides the 10-year and lifetime risk of ASCVD events and the 8-year risk of developing diabetes. The lipid panel results will aid in the assessment of ASCVD. Assessment of 10-year risk of a first atherosclerotic cardiovascular (ASCVD) event is recommended by the 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. These guidelines recommend initiating statin therapy based on 10-year ASCVD risk score. Assessment of 8-year risk of developing diabetes mellitus is based on laboratory test results with anthropomorphic data and family history. This algorithm was developed in the Framingham cohort, and is intended to aid in the identification of patients at risk for developing diabetes, permitting pharmacological or lifestyle interventions.

IMPORTANT: For risk calculations to be performed, the following patient-specific information must be provided and recorded at the time of specimen collection:

• Age: Years 
• Gender: M (for male) or F (for female) 
• Height Feet: Feet 
• Height Inches: Inches 
• Weight: lbs 
• Race-African American: Y (for yes) or N (for no) 
• Systolic Blood Pressure: mmHg
• Diastolic Blood Pressure: mmHg
• Treatment for High B.P.: Y (for yes) or N (for no) 
• Diabetes Status: Y (for yes) or N (for no)
• Parental History of Diab: Y (for yes) or N (for no) 
• Smoking Status: Y (for Yes) or N (for no)

• Apolipoprotein A-1, Cardio IQ™
• Cardio IQ(R) Homocysteine
• CARDIO IQ(R) LP PLA2 ACTIVITY
• hs-CRP, Cardio IQ™
• Lipid Panel, Cardio IQ™
• Lipoprotein (a), Cardio IQ™
• Lipoprotein Fractionation, Ion Mobility, Cardio IQ™
• Omega-3 and -6 Fatty Acids, Plasma

• Apolipoprotein A-1, Cardio IQ™
• Cardio IQ(R) Homocysteine
• CARDIO IQ(R) LP PLA2 ACTIVITY
• Fibrinogen Antigen, Nephelometry, Cardio IQ™
• hs-CRP, Cardio IQ™
• Lipid Panel, Cardio IQ™
• Lipoprotein (a), Cardio IQ™
• Lipoprotein Fractionation, Ion Mobility, Cardio IQ™
• Omega-3 and -6 Fatty Acids, Plasma

• Apolipoprotein A-1, Cardio IQ™
• Cardio IQ(R) Homocysteine
• CARDIO IQ(R) LP PLA2 ACTIVITY
• CARDIO IQ(R) MYELOPEROXIDASE (MPO)
• hs-CRP, Cardio IQ™
• Lipid Panel, Cardio IQ™
• Lipoprotein (a), Cardio IQ™
• Lipoprotein Fractionation, Ion Mobility, Cardio IQ™
• Omega-3 and -6 Fatty Acids, Plasma

• Apolipoprotein A-1, Cardio IQ™
• Cardio IQ(R) Homocysteine
• CARDIO IQ(R) LP PLA2 ACTIVITY
• CARDIO IQ(R) MYELOPEROXIDASE (MPO)
• Fibrinogen Antigen, Nephelometry, Cardio IQ™
• hs-CRP, Cardio IQ™
• Lipid Panel, Cardio IQ™
• Lipoprotein (a), Cardio IQ™
• Lipoprotein Fractionation, Ion Mobility, Cardio IQ™
• Omega-3 and -6 Fatty Acids, Plasma

Cardio IQ Lp-PLA2 Activity

Clinical Significance

Lipoprotein-associated phospholipase A2 (Lp-PLA2), also known as platelet activating factor Acetylhydrolase, is an inflammatory enzyme that circulates bound mainly to low density lipoproteins and has been found to be localized and enriched in atherosclerotic plaques. In multiple clinical trials, Lp-PLA2 activity has been shown to be an independent predictor of coronary heart disease and stroke in the general population. Measurement of Lp-PLA2 may be used along with traditional cardiovascular risk factor measures for identifying individuals at higher risk of cardiovascular disease events. Clinical management may include beginning or intensifying risk reduction strategies. The activity assay is an enzyme assay run on an automated chemistry platform.